GeneHealth - Your precision medicine

Myxoid Liposarcoma

Disease Details

Family Health Simplified

Buy Membership

Description: Myxoid liposarcoma is a malignant soft tissue tumor characterized by the presence of lipoblasts in a myxoid (mucoid) stroma, often occurring in the deep soft tissues of the limbs, particularly the thighs.
Type: Myxoid liposarcoma is a type of soft tissue sarcoma. It is generally considered sporadic, meaning it typically does not follow a pattern of genetic transmission and is not usually inherited. However, it often involves specific genetic abnormalities, such as the translocation t(12;16)(q13;p11), that occur in the tumor cells themselves.
Signs And Symptoms: Signs and symptoms of myxoid liposarcoma can include:
- A noticeable lump or mass, usually in the thigh or other extremities
- Pain or tenderness in the affected area
- Swelling
- Reduced range of motion if the tumor is near a joint
- Neurological symptoms if the tumor compresses nerves

Early stages may be asymptomatic, and signs can vary based on the tumor's size and location.
Prognosis: Myxoid liposarcoma is a type of soft tissue sarcoma characterized by its myxoid (mucoid) matrix and presence of lipogenic (fat-forming) cells. The prognosis for myxoid liposarcoma generally depends on various factors such as the tumor's size, location, histological grade, and the presence of metastasis. In general, myxoid liposarcomas tend to have a more favorable prognosis compared to other types of liposarcomas, especially when detected early and treated appropriately. The five-year survival rate can be relatively high for localized cases but decreases if the disease has spread.
Onset: Myxoid liposarcoma is a rare type of cancer that primarily affects the soft tissues, particularly fat tissues. The onset typically occurs in adults aged 30 to 60. Signs and symptoms might include a slowly growing, painless mass or lump in the deep soft tissues of the limbs, especially the thighs. Early detection and diagnosis are crucial for effective treatment.
Prevalence: The exact prevalence of myxoid liposarcoma isn't well-documented, but it is considered a relatively rare type of cancer. Liposarcomas overall account for about 15-20% of all soft tissue sarcomas, and myxoid liposarcomas make up approximately 30-40% of all liposarcomas. This means it constitutes a small fraction of all malignancies.
Epidemiology: Myxoid liposarcoma is a subtype of liposarcoma, a cancer that arises in fat cells. It is relatively rare, contributing to about 20-30% of all liposarcomas. This cancer typically affects adults, with a peak incidence between the ages of 30 and 50. It does not show a strong gender preference and can occur in various locations in the body, most commonly in the deep soft tissues of the extremities, particularly the thigh. Myxoid liposarcoma is characterized by a specific genetic translocation, commonly t(12;16)(q13;p11), which helps in its diagnosis.
Intractability: Myxoid liposarcoma is a malignant tumor that originates in fat tissue and requires specialized treatment. While it can be challenging to treat due to its potential for recurrence and metastasis, especially to the lungs, it is not considered entirely intractable. With appropriate intervention, including surgery, radiation therapy, and sometimes chemotherapy, a number of patients can achieve good outcomes. Early detection and multidisciplinary care are critical in managing the disease effectively.
Disease Severity: Myxoid liposarcoma is a malignant tumor originating from fat tissue, characterized by its mix of fat cells and a gelatinous myxoid matrix. Its severity can vary depending on factors such as tumor size, location, and stage at diagnosis. It is generally considered an intermediate to high-grade malignancy, with potential for local recurrence and metastasis, particularly to the lungs. Early detection and treatment are crucial for better outcomes.
Healthcare Professionals: Disease Ontology ID - DOID:5363
Pathophysiology: Myxoid liposarcoma is a subtype of liposarcoma, which is a malignant tumor derived from fat cells. Pathophysiologically, it is characterized primarily by the presence of a specific chromosomal translocation, t(12;16)(q13;p11), that leads to the fusion of the DDIT3 (CHOP) gene on chromosome 12 to the FUS gene on chromosome 16. This genetic alteration results in the production of a fusion protein that disrupts normal cell differentiation and promotes abnormal cell growth.

Histologically, myxoid liposarcoma is marked by a gelatinous extracellular matrix with a 'myxoid' appearance, immature lipoblasts, and a network of capillaries forming a "chicken-wire" pattern. The tumor cells have a tendency to infiltrate surrounding tissues, and while local recurrence is common, metastasis often involves unusual sites such as the retroperitoneum and bones. The pathophysiology involves both proliferative and neovascular characteristics that contribute to its aggressive nature and potential for metastasis.
Carrier Status: Myxoid liposarcoma is a type of cancer that arises in fat tissue and typically occurs in the deep soft tissues. Carrier status is not applicable to myxoid liposarcoma since it is not a hereditary disease. There are no carriers for this condition as it results from acquired genetic mutations in the affected cells rather than inherited genetic factors.
Mechanism: Myxoid liposarcoma is a subtype of liposarcoma, a malignant tumor originating from fat tissue. Its mechanism involves the transformation and proliferation of adipocytes or primitive mesenchymal cells into malignant cells.

Molecularly, the disease is often characterized by a specific chromosomal translocation, notably t(12;16)(q13;p11), which results in a fusion gene known as FUS-DDIT3 (also referred to as FUS-CHOP). This fusion gene disrupts normal cellular functions by affecting key processes like cell differentiation, proliferation, and apoptosis, leading to the growth of malignant myxoid liposarcoma cells. This translocation is considered a major driver of the pathogenesis of myxoid liposarcoma and helps differentiate it from other liposarcoma subtypes.
Treatment: Myxoid liposarcoma is typically treated with a combination of surgery, radiation therapy, and sometimes chemotherapy. The primary treatment is surgical resection to remove the tumor, aiming for clear margins to minimize recurrence. Radiation therapy is often provided either preoperatively or postoperatively to control local disease, especially if the tumor is large or in a challenging location. Chemotherapy is used less commonly but may be considered in cases with a high risk of metastasis or when the tumor is not amenable to complete surgical removal.
Compassionate Use Treatment: For myxoid liposarcoma, compassionate use treatments, off-label, or experimental options may include:

1. **Trabectedin (Yondelis)**: Approved for soft tissue sarcoma in some regions, it's available via compassionate use in others.
2. **Eribulin (Halaven)**: While primarily used for breast cancer, it's being researched for efficacy in liposarcoma.
3. **Pazopanib (Votrient)**: Used off-label for sarcomas, including myxoid liposarcoma.
4. **Chemotherapy Combinations**: Innovative combinations of drugs like gemcitabine and docetaxel.
5. **Immunotherapy**: Agents like pembrolizumab are undergoing trials for effectiveness in soft tissue sarcomas.
6. **Targeted Therapy**: Investigational drugs aiming specific mutations present in some myxoid liposarcomas.
7. **Clinical Trials**: Participation in trials for cutting-edge therapies like CAR-T cell therapy or novel kinase inhibitors.

Consulting with a specialist in sarcomas is crucial to explore these treatments effectively.
Lifestyle Recommendations: Lifestyle recommendations for myxoid liposarcoma primarily focus on supporting overall health and well-being, as well as managing the effects of treatment. Key recommendations include:

1. **Healthy Diet**: Eat a balanced diet rich in fruits, vegetables, lean proteins, and whole grains to support your immune system and general health.

2. **Regular Exercise**: Engage in regular physical activity as tolerated to maintain strength, improve mood, and support cardiovascular health. Always consult with your healthcare provider before beginning any exercise regimen.

3. **Regular Follow-Ups**: Keep all scheduled appointments with your healthcare team to monitor for recurrence and manage any side effects of treatment.

4. **Adequate Rest**: Ensure you are getting enough sleep and rest to help your body recover from treatments like surgery, radiation, or chemotherapy.

5. **Alcohol and Smoking**: Avoid smoking and limit alcohol consumption, as these can compromise your immune system and overall health.

6. **Stress Management**: Utilize stress-reduction techniques such as mindfulness, meditation, or counseling to help cope with the emotional and physical stress of the disease.

7. **Support Systems**: Engage with support groups or seek support from friends and family to help manage the emotional aspects of living with cancer.

It's essential to develop a personalized plan in consultation with your healthcare provider, as they can provide specific recommendations tailored to your condition and treatment plan.
Medication: There is no specific medication approved solely for the treatment of myxoid liposarcoma. The management usually involves a combination of surgery, radiation therapy, and sometimes chemotherapy. Common chemotherapeutic agents used include doxorubicin and ifosfamide. It's crucial for the treatment plan to be tailored to the individual patient's case, often involving a multidisciplinary team. Always follow the treatment recommendations provided by your healthcare provider.
Repurposable Drugs: Myxoid liposarcoma is a subtype of liposarcoma characterized by myxoid (mucoid) matrix and a propensity for specific genetic alterations, such as the FUS-DDIT3 (formerly known as FUS-CHOP) fusion gene.

**Repurposable Drugs:**
1. **Trabectedin**: Originally used for soft tissue sarcomas, it has shown efficacy in myxoid liposarcoma, particularly those with the FUS-DDIT3 fusion gene, by targeting the transcriptional machinery.
2. **Pazopanib**: This tyrosine kinase inhibitor, used for renal cell carcinoma and soft tissue sarcomas, has demonstrated activity against liposarcomas and might be considered for off-label use.
3. **Eribulin**: A microtubule dynamics inhibitor approved for metastatic breast cancer, it has shown promise in liposarcoma treatment.

Nan refers to any items mentioned classified under the assessed drugs.
Metabolites: For myxoid liposarcoma, key metabolites of interest often involve lipid metabolism, given the tumor's origin in fat tissue. Abnormal fatty acid synthesis and metabolism can be characteristic of these tumors. Specific metabolites may include:

1. Triglycerides
2. Cholesterol esters
3. Phospholipids

Additionally, alterations in metabolites linked to the tumor microenvironment, such as lactate and citrate, might be observed, reflecting changes in energy metabolism (Warburg effect).

For more targeted data, metabolomic profiling specific to myxoid liposarcoma would provide detailed insights into the unique metabolite changes in these tumors.
Nutraceuticals: There is no established evidence that nutraceuticals have a significant impact on the treatment or management of myxoid liposarcoma. Standard treatment typically involves surgical resection, radiation therapy, and sometimes chemotherapy, depending on the case specifics. Always consult an oncologist for guidance tailored to individual medical conditions.
Peptides: Myxoid liposarcoma is a subtype of liposarcoma characterized by myxoid (mucoid) stroma. Regarding peptides, these small chains of amino acids can be used in diagnostic or therapeutic approaches. For instance, certain peptides can be developed as biomarkers for the disease or used in targeted therapies to deliver drugs specifically to tumor cells.

Nanotechnology (nan) plays a role in potentially enhancing the treatment and detection of myxoid liposarcoma. Nanoparticles can be engineered to deliver chemotherapeutic agents directly to cancer cells, improving drug efficacy and reducing side effects. Additionally, nanoscale imaging agents can help in better visualization of the tumor during diagnostic procedures.